SCHEMBL5004640

SCHEMBL5004640

Cc1ccc(C2CC(N3CCCC(C(=O)O)C3)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
KDM2B Q8NHM5 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.44
HRH3 Q9Y5N1 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
LTA4H P09960 1/20 0.42
SLC18A3 Q16572 1/20 0.42
SLC6A11 P48066 1/20 0.41
AGTR2 P50052 3/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HRH1 P35367 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5009505 0.88 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2LTA4HAGTR2HTR2A
SCHEMBL5007409 0.87 AKR1C3 (0.51) ALDH1A1TSHRHSD17B10LTA4HAGTR2
SCHEMBL5004398 0.79 ALDH1A1 (0.48) ALDH1A1KDM2BSMN1; SMN2HTR2AHTR2C
SCHEMBL1587410 0.79 AKR1C3 (0.54) NPC1RAB9ASLC18A3AGTR2HTR2A
SCHEMBL17124882 0.77 SLC18A3 (0.44) ALDH1A1KDM2BSMN1; SMN2NPC1TP53
SCHEMBL6373468 0.76 CYP2D6 (0.59) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL16015140 0.74 LIPE (0.44) ALDH1A1SMN1; SMN2NPC1TP53TSHR
SCHEMBL5004123 0.73 OPRM1 (0.44) ALDH1A1HTR2AHTR2CHRH1HTR2B
SCHEMBL27754827 0.72 SLC6A11 (0.50) ALDH1A1TP53KDM4EMEN1KMT2A
SCHEMBL15787994 0.72 SLC18A3 (0.53) ALDH1A1SMN1; SMN2NPC1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 ALDH1A1 3777/4885KDM2B 3075/4885SMN1; SMN2 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.